News Amneal Pharmaceuticals, Inc.

Equities

AMRX

US03168L1052

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-15 pm EDT			5-day change	1st Jan Change
5.54 ^USD	+0.36%		-7.67%	-8.73%

Apr. 12	Bausch Health Gets 'Positive' Court Ruling on Xifaxan With Market Odds of Bausch + Lomb Distribution at 32%, RBC Says	MT
Apr. 12	RBC Notes "Positive" Appellate Court Ruling For Bausch Health, But Thinks Market Assigning ~32% BLCO Distribution Odds	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Bausch Health Gets 'Positive' Court Ruling on Xifaxan With Market Odds of Bausch + Lomb Distribution at 32%, RBC Says	Apr. 12	MT
RBC Notes "Positive" Appellate Court Ruling For Bausch Health, But Thinks Market Assigning ~32% BLCO Distribution Odds	Apr. 12	MT
Amneal to Report First Quarter 2024 Results on May 3, 2024	Apr. 10	BU
TSX ends flat as gold stocks drop, mood cautious ahead of rate decision	Apr. 08	RE
Bausch Health Up Near 0.4% In US Premarket After Announcing Patent Lawsuit Against Amneal Pharmaceuticals	Apr. 08	MT
North American Morning Briefing : Inflation Data, -2-	Apr. 08	DJ
Amneal to Ring the Nasdaq Closing Bell on April 2, 2024	Mar. 28	BU
Amneal Pharmaceuticals, LLC. Issues a Nationwide Voluntary Recall of Vancomycin Hydrochloride for Oral Solution USP, 250mg/5mL, due to the potential for some bottles to be super potent which may be harmful	Mar. 28	AQ
Amneal Pharmaceuticals : LLC. Issues a Nationwide Voluntary Recall of Vancomycin Hydrochloride for Oral Solution USP, 250mg/5mL, due to the potential for some bottles to be super potent which may be harmful.	Mar. 27	PU
Amneal Pharma Gets FDA Nod for Infection Fighting Drug Combination	Mar. 25	DJ
Amneal Pharmaceuticals Receives FDA Approval for Ear Infection Treatment	Mar. 25	MT
Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension	Mar. 25	BU
Amneal Pharmaceuticals, Inc Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension	Mar. 25	CI
Transcript : Amneal Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 08:30 AM	Mar. 13
Goldman Sachs Adjusts Price Target on Amneal Pharmaceuticals to $6.25 From $5.50, Maintains Buy Rating	Mar. 04	MT
Amneal Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results	Mar. 04	AQ
Sector Update: Health Care Stocks Edge Higher Premarket Friday	Mar. 01	MT
Sector Update: Health Care	Mar. 01	MT
Transcript : Amneal Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 01, 2024	Mar. 01
Exchange-Traded Funds Higher, Equity Futures Lower Pre-Bell Friday as Traders Turn Cautious After Major US Data Releases	Mar. 01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Amneal Pharmaceuticals, Inc.

Equities

AMRX

US03168L1052

Summary

Filters